We O
consider O
this O
episode O
of O
SIADH B
to O
be O
the O
result O
of O
a O
combination O
of O
factors O
including O
a O
weakness B
of I
the I
central I
nervous I
system I
and O
the O
long O
- O
term O
administration O
of O
VPA O
. O

Liver O
biopsy O
showed O
evidence O
of O
nonspecific O
drug B
- I
induced I
acute I
liver I
injury I
. O

Does O
hormone O
therapy O
for O
the O
treatment O
of O
breast B
cancer I
have O
a O
detrimental B
effect I
on I
memory I
and I
cognition I
? O

Chronic B
infection I
with I
hepatitis I
C I
virus I
( O
HCV O
) O
can O
progress O
to O
cirrhosis B
, O
hepatocellular B
carcinoma I
, O
and O
end B
- I
stage I
liver I
disease I
. O

This O
neuropathy B
was O
gradually O
resolving O
; O
however O
, O
after O
the O
patient O
received O
allogeneic O
bone O
marrow O
transplantation O
, O
the O
symptoms O
worsened O
, O
with O
the O
development O
of O
graft B
- I
versus I
- I
host I
disease I
, O
and O
the O
symptoms O
subsequently O
responded O
to O
methylprednisolone O
. O

Diffusion O
weighted O
imaging O
( O
DWI O
) O
of O
all O
patients O
revealed O
well O
demarcated O
hyperintense O
lesions B
within I
the I
subcortical I
white I
matter I
of O
the O
cerebral O
hemispheres O
and O
the O
corpus O
callosum O
, O
corresponding O
to O
areas O
of O
decreased O
proton O
diffusion O
on O
apparent O
diffusion O
coefficient O
( O
ADC O
) O
maps O
( O
available O
in O
21 O
/ O
27 O
patients O
) O
. O

DWI O
findings O
in O
this O
cohort O
are O
indicative O
of O
cytotoxic B
oedema I
within I
cerebral I
white I
matter I
and O
lend O
support O
to O
an O
at O
least O
partially O
reversible O
metabolic O
derangement O
as O
the O
basis O
for O
this O
syndrome O
. O

Graft B
- I
versus I
- I
host I
disease I
prophylaxis O
with O
everolimus O
and O
tacrolimus O
is O
associated O
with O
a O
high O
incidence O
of O
sinusoidal B
obstruction I
syndrome I
and O
microangiopathy B
: O
results O
of O
the O
EVTAC O
trial O
. O

A O
calcineurin O
inhibitor O
combined O
with O
methotrexate O
is O
the O
standard O
prophylaxis O
for O
graft B
- I
versus I
- I
host I
disease I
( O
GVHD B
) O
after O
allogeneic O
hematopoietic O
stem O
cell O
transplantation O
( O
HSCT O
) O
. O

We O
describe O
a O
42 O
- O
year O
- O
old O
woman O
who O
developed O
superior O
sagittal B
and I
left I
transverse I
sinus I
thrombosis I
associated O
with O
prolonged O
epsilon O
- O
aminocaproic O
acid O
therapy O
for O
menorrhagia B
. O

Anthony B
' I
s I
fire I
, O
then O
and O
now O
: O
a O
case O
report O
and O
historical O
review O
. O

Anthony B
' I
s I
fire I
persists O
. O

Acute B
experimental I
models I
of I
renal I
damage I
to O
the O
proximal O
tubular O
, O
glomerular O
, O
and O
papillary O
regions O
of O
the O
rat O
were O
produced O
by O
administration O
of O
hexachloro O
- O
1 O
: O
3 O
- O
butadiene O
( O
HCBD O
) O
, O
puromycin O
aminonucleoside O
( O
PAN O
) O
, O
and O
2 O
- O
bromoethylamine O
( O
BEA O
) O
, O
respectively O
. O

A O
muscle O
biopsy O
in O
this O
patient O
showed O
loss B
of I
thick I
, I
myosin I
filaments I
. O

The O
weakness B
in O
these O
patients O
is O
due O
to O
pathology B
at I
both I
the I
neuromuscular I
junction I
( O
most O
likely O
due O
to O
ND O
- O
NMBA O
) O
and O
muscle O
( O
most O
likely O
due O
to O
corticosteroids O
) O
. O

Forty O
patients O
with O
Non B
- I
Hodgkin I
' I
s I
Lymphoma I
treated O
with O
vincristine O
between O
1984 O
and O
1990 O
( O
cumulative O
dose O
12 O
mg O
in O
18 O
- O
24 O
weeks O
) O
were O
investigated O
in O
order O
to O
evaluate O
the O
long O
term O
effects O
of O
vincristine O
on O
the O
peripheral O
nervous O
system O
. O

Chemotherapy O
of O
advanced O
inoperable O
non B
- I
small I
cell I
lung I
cancer I
with O
paclitaxel O
: O
a O
phase O
II O
trial O
. O

Two O
phase O
II O
trials O
of O
24 O
- O
hour O
paclitaxel O
infusions O
in O
chemotherapy O
- O
naive O
patients O
with O
stage O
IIIB O
or O
IV O
non B
- I
small I
cell I
lung I
cancer I
( O
NSCLC B
) O
reported O
response O
rates O
of O
21 O
% O
and O
24 O
% O
. O

Leg B
and I
/ I
or I
back I
pain I
is O
associated O
with O
the O
intrathecal O
use O
of O
hyperbaric O
5 O
% O
lignocaine O
. O

CaCl2 O
therapy O
may O
possibly O
worsen O
both O
cardiovascular B
and I
central I
nervous I
system I
toxicity I
. O

Granulosa B
cell I
tumor I
of I
the I
ovary I
associated O
with O
antecedent O
tamoxifen O
use O
. O

After O
an O
additional O
17 O
months O
of O
elevated O
serum O
transaminases O
, O
the O
patient O
was O
found O
to O
have O
a O
stage O
Ic O
granulosa B
cell I
tumor I
of I
the I
ovary I
. O

Structural B
and I
functional I
impairment I
of I
mitochondria I
in O
adriamycin O
- O
induced O
cardiomyopathy B
in O
mice O
: O
suppression O
of O
cytochrome O
c O
oxidase O
II O
gene O
expression O
. O

